11¿ù 6ÀÏ (±Ý) | |||
---|---|---|---|
09:45 | 10:00 | Àλ縻 | ´ëÇÑÇ÷¾×ÇÐȸ ȸ Àå À±¼º¼ö ÀÌ»çÀå ÀÌÁ¦È¯ |
10:00 | 12:00 | ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ | |
Session I: Microenvironment and immune landscape in multiple myeloma | ÁÂÀå : ÀÌÁ¦Áß | ||
10:00 | 10:30 | Role of microenvironment in the pathogenesis of multiple myeloma VOD ´Ù½Ãº¸±â |
±è¸í½Å(°¡Å縯ÀÇ´ë) |
10:30 | 11:00 | Immune landscape in multiple myeloma VOD ´Ù½Ãº¸±â |
°í¿µÀÏ(¼¿ïÀÇ´ë) |
Session II: Treatment of transplant-eligible multiple myeloma | ÁÂÀå : ¹Îâ±â | ||
11:00 | 11:30 | Evolving therapeutic options in the induction treatment for transplant-eligible multiple myeloma VOD ´Ù½Ãº¸±â |
Á¶Àçö(¿ï»êÀÇ´ë) |
11:30 | 12:00 | Role of autologous stem cell transplant in elderly patients and post-transplant therapeutic options VOD ´Ù½Ãº¸±â |
¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ) |
12:00 | 13:00 | Á¡½É | |
13:00 | 15:00 | °ñ¼öÁõ½ÄÁ¾¾ç¿¬±¸È¸ | |
13:00 | 13:30 | Diagnostic workflow for erythrocytosis and thrombocytosis VOD ´Ù½Ãº¸±â |
¼ºÈÁ¤(°í·ÁÀÇ´ë) |
13:30 | 14:00 | Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN VOD ´Ù½Ãº¸±â |
À̼ºÀº(°¡Å縯ÀÇ´ë) |
14:00 | 14:30 | Post-ET/PV Myelofibrosis vs Primary Myelofibrosis VOD ´Ù½Ãº¸±â |
±è¹Î°æ(¿µ³²ÀÇ´ë) |
14:30 | 15:00 | A significance of hydroxyurea resistance in MPN patients VOD ´Ù½Ãº¸±â |
±è¼º¿ë(°Ç±¹ÀÇ´ë) |
11:30 | 12:00 | The role of interferon in MPNs VOD ´Ù½Ãº¸±â |
À±¼®À±(¼øõÇâÀÇ´ë) |
15:00 | 15:15 | ÈÞ½Ä | |
15:15 | 18:15 | ¼ºÀÎ/¼Ò¾ÆALL ¿¬±¸È¸ | |
Important but unsolved issues in adult ALL | ÁÂÀå : µµ¿µ·Ï | ||
15:15 | 15:45 | Molecular genetics in adult B-cell ALL VOD ´Ù½Ãº¸±â |
Á¤¼ºÈÆ(Àü³²ÀÇ´ë) |
15:45 | 16:15 | Molecular genetics in adult T-cell ALL VOD ´Ù½Ãº¸±â |
À±ÀçÈ£(°¡Å縯ÀÇ´ë) |
16:15 | 16:45 | Treatment of relapsed/refractory T-ALL in adult patients VOD ´Ù½Ãº¸±â |
¹éµ¿¿ø(°æºÏÀÇ´ë) |
16:45 | 17:00 | NGS MRD ±â¹Ý ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ´Ù±â°ü ¿¬±¸°èȹ VOD ´Ù½Ãº¸±â |
ÃÖÁ¤À±(¼¿ïÀÇ´ë) |
17:00 | 17:15 | NGS MRD ºÐ¼®¹æ¹ý 1 VOD ´Ù½Ãº¸±â |
±è¸í½Å(°¡Å縯ÀÇ´ë) |
17:15 | 17:30 | NGS MRD ºÐ¼®¹æ¹ý 2 VOD ´Ù½Ãº¸±â |
¼º¹®¿ì(¼¿ïÀÇ´ë) |
17:30 | 17:45 | NGS MRD ºÐ¼®¹æ¹ý 3 VOD ´Ù½Ãº¸±â |
À̽ÂÅÂ(¿¬¼¼ÀÇ´ë) |
17:45 | 18:15 | ÆгÎÅäÀÇ VOD ´Ù½Ãº¸±â |
11¿ù 07ÀÏ (Åä¿äÀÏ) | |||
---|---|---|---|
09:00 | 10:00 | ÆòÀÇ¿øȸ(¿Â¶óÀÎ) | |
10:00 | 12:00 | AML/MDS¿¬±¸È¸ | |
Gap & perspective of targeted therapies for AML/MDS | ÁÂÀå : ±èÇüÁØ/Á¤ÁØ¿ø | ||
10:00 | 10:30 | FLT3 inhibitors & Bcl-2 inhibitor for adult AML VOD ´Ù½Ãº¸±â |
Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë) |
10:30 | 11:00 | Targeting gene mutations and epigenetic regulators for pediatric AML VOD ´Ù½Ãº¸±â |
À¯°ÇÈñ(¼º±Õ°üÀÇ´ë) |
11:00 | 11:30 | What comes next to HMA for MDS? VOD ´Ù½Ãº¸±â |
±èÀ¯Áø(°¡Å縯ÀÇ´ë) |
11:30 | 12:00 | Multi parameterflow cytometry for AML/MDS VOD ´Ù½Ãº¸±â |
¼ÛÀç¿ì(¿¬¼¼ÀÇ´ë) |
11¿ù 6ÀÏ (±Ý) | |||
---|---|---|---|
09:45 | 10:00 | Àλ縻 | ´ëÇÑÇ÷¾×ÇÐȸ ȸ Àå À±¼º¼ö ÀÌ»çÀå ÀÌÁ¦È¯ |
10:00 | 12:00 | ÀûÇ÷±¸Áúȯ¿¬±¸È¸ | |
10:00 | 10:05 | (10:00-10:05) À§¿øÀå Àλ縻 & ¼Ò°³ | ÀûÇ÷±¸Áúȯ¿¬±¸È¸ À§¿øÀå ÃÖÇü¼ö |
Session I | ÁÂÀå : ÃÖÇü¼ö/Á¤Çý¸² | ||
10:05 | 10:20 | ¼±Ãµ¿ëÇ÷ºóÇ÷ÀÇ epidemiology study °æÇè°ú °³¼±¹æÇâ VOD ´Ù½Ãº¸±â |
½É¿¹Áö(°è¸íÀÇ´ë) |
10:20 | 10:35 | ¼±Ãµ¿ëÇ÷ºóÇ÷ ȤÀº ¼±ÃµºóÇ÷ÀÇ ±¹³» Registry ±¸ÃàÀÇ Çʿ伺 VOD ´Ù½Ãº¸±â |
ÃÖÈñ¿ø(µ¿¾ÆÀÇ´ë) |
Session II | ÁÂÀå : ÇÑÁø¿µ | ||
10:35 | 11:05 | NGS¸¦ È°¿ëÇÑ ºóÇ÷ÀÇ Áø´Ü VOD ´Ù½Ãº¸±â |
Ȳ»ó¹Ì(¼¿ïÀÇ´ë) |
11:05 | 11:10 | Áú¹® & discussion | |
Session III | ÁÂÀå : ÇÏÁ¤¿Á/±èÀÎÈ£ | ||
11:10 | 11:30 | Autoimmune hemolytic anemia ¼ºÀο¡¼ÀÇ °æÇè VOD ´Ù½Ãº¸±â |
¼ÛÀÍÂù(Ãæ³²ÀÇ´ë) |
11:30 | 11:50 | Autoimmune hemolytic anemia ¼Ò¾Æ¿¡¼ÀÇ °æÇè VOD ´Ù½Ãº¸±â |
ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë) |
11:50 | 12:00 | Áú¹® & discussion | |
12:00 | 13:00 | Á¡½É | |
13:00 | 15:00 | Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ | |
13:00 | 13:05 | Opening remarks | Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ À§¿øÀå ÀÓÈ£ÁØ |
Session I: Recent updates in LCH | ÁÂÀå : ¼Á¾Áø | ||
13:05 | 13:25 | Updates on target agents of LCH VOD ´Ù½Ãº¸±â |
Çѽ¹Î(¿¬¼¼ÀÇ´ë) |
13:25 | 13:45 | CNS LCH VOD ´Ù½Ãº¸±â |
È«°æÅÃ(¼¿ïÀÇ´ë) |
Session II: Recent updates in HLH | ÁÂÀå : À¯Ã¶ÁÖ | ||
13:45 | 14:05 | Updates on target agents of HLH VOD ´Ù½Ãº¸±â |
ÀÌÀç¿í(°¡Å縯ÀÇ´ë) |
14:05 | 14:25 | Understanding of MAS VOD ´Ù½Ãº¸±â |
ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë) |
14:25 | 14:45 | Real world experience for haploidentical HSCT in HLH VOD ´Ù½Ãº¸±â |
ÀÓÈ£ÁØ(¿ï»êÀÇ´ë) |
14:45 | 14:50 | Closing remarks | Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ À§¿øÀå ÀÓÈ£ÁØ |
15:00 | 15:15 | ÈÞ½Ä | |
15:15 | 18:15 | Ç÷ÀüÁöÇ÷¿¬±¸È¸ | |
15:15 | 15:20 | Opening remarks | |
Session I: : Pregnancy | ÁÂÀå : ¿Àµµ¿¬/±èÁø¼® | ||
15:20 | 15:40 | Obstetric issues in bleeding disorders VOD ´Ù½Ãº¸±â |
À¯ÄèÇÑ(°¡ÃµÀÇ´ë) |
15:40 | 16:00 | Obstetric issues in thrombophilic conditions (IVF µî Æ÷ÇÔ) VOD ´Ù½Ãº¸±â |
¾È¼¿¬(Àü³²ÀÇ´ë) |
16:00 | 16:10 | Session Q&A VOD ´Ù½Ãº¸±â |
|
16:10 | 16:20 | ÈÞ½Ä | |
Session II: Bleeding disorders | ÁÂÀå : ¹æ¼ö¹Ì/±è¼ºÇö | ||
16:20 | 16:40 | Congenital bleeding disorder VOD ´Ù½Ãº¸±â |
ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë) |
16:40 | 17:00 | Acquired hemophilia VOD ´Ù½Ãº¸±â |
Çö½Å¿µ(¿¬¼¼ÀÇ´ë) |
17:00 | 17:10 | Session Q&A | |
17:10 | 17:15 | Closing remarks |
11¿ù 07ÀÏ (Åä¿äÀÏ) | |||
---|---|---|---|
09:00 | 10:00 | ÆòÀÇ¿øȸ(¿Â¶óÀÎ) | |
10:00 | 12:00 | Ç÷¿ìº´¿¬±¸È¸ | |
10:00 | 10:25 | Novel agents and current treatment changes in hemophilia : Emicizumab VOD ´Ù½Ãº¸±â |
ÇÑÁ¤¿ì(¿¬¼¼ÀÇ´ë) |
10:25 | 10:50 | Novel therapeutics and current treatment changes in hemophilia : Fitusiran, anti-TFPI and gene therapy VOD ´Ù½Ãº¸±â |
¹Ú¿µ½Ç(°æÈñÀÇ´ë) |
10:50 | 10:55 | Questions/Answers and Discussion (I) | |
10:55 | 11:20 | Multidisciplinary clinic and role of the hematologist : Hemostatic support for the management in the multidisciplinary clinics VOD ´Ù½Ãº¸±â |
¹éÈñÁ¶(Àü³²ÀÇ´ë) |
11:20 | 11:45 | Recent update on the clinical guideline for hemophilia VOD ´Ù½Ãº¸±â |
ÃÖÀºÁø(´ë±¸°¡Å縯ÀÇ´ë) |
11:45 | 11:50 | Questions/answers and discussion | |
11:50 | 12:00 | ÃÑȸ (¿Â¶óÀÎ) |